Fibrocell Science (NASDAQ:FCSC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
Separately, HC Wainwright set a $6.00 target price on shares of Fibrocell Science and gave the stock a “buy” rating in a research note on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. Fibrocell Science presently has an average rating of “Hold” and a consensus price target of $3.94.
Shares of Fibrocell Science (NASDAQ:FCSC) traded down $0.00 during mid-day trading on Wednesday, reaching $0.66. 98,340 shares of the company’s stock traded hands, compared to its average volume of 877,500. The company has a market capitalization of $14.78, a price-to-earnings ratio of -0.36 and a beta of 0.43. Fibrocell Science has a twelve month low of $0.61 and a twelve month high of $4.64.
Fibrocell Science (NASDAQ:FCSC) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.07. analysts forecast that Fibrocell Science will post -1.63 earnings per share for the current year.
In other Fibrocell Science news, major shareholder Randal J. Kirk bought 2,727,273 shares of Fibrocell Science stock in a transaction dated Monday, December 11th. The stock was purchased at an average price of $0.77 per share, for a total transaction of $2,100,000.21. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.10% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Armistice Capital LLC purchased a new position in shares of Fibrocell Science in the fourth quarter worth about $393,000. Third Security LLC increased its stake in shares of Fibrocell Science by 49.2% in the fourth quarter. Third Security LLC now owns 8,267,413 shares of the company’s stock worth $5,292,000 after purchasing an additional 2,727,273 shares in the last quarter. FNY Partners Fund LP purchased a new position in shares of Fibrocell Science in the fourth quarter worth about $129,000. Pura Vida Investments LLC purchased a new position in Fibrocell Science during the third quarter valued at approximately $909,000. Finally, Parametric Portfolio Associates LLC grew its stake in Fibrocell Science by 264.0% during the second quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock valued at $194,000 after acquiring an additional 35,000 shares in the last quarter. Hedge funds and other institutional investors own 43.00% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Fibrocell Science (FCSC) Downgraded by Zacks Investment Research” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/14/fibrocell-science-fcsc-downgraded-by-zacks-investment-research.html.
About Fibrocell Science
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.